This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy
by Arpita Dutt
A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
by Arpita Dutt
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
by Zacks Equity Research
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal
by Arpita Dutt
While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.
Top Research Reports for Amazon, AbbVie & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), AbbVie (ABBV) and Biogen (BIIB).
Biogen Acquires Worldwide License for Alkermes' MS Candidate
by Zacks Equity Research
Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.
Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil
Should You Buy the Beaten Down Blue-Chip Stocks?
by Tracey Ryniec
Just because a stock plunges to multi-year lows, that doesn't mean it's a value stock.
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
by Arpita Dutt
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.
Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y
by Zacks Equity Research
Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.
Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.
Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Biogen (BIIB) Beats on Q3 Earnings and Revenue
by Zacks Equity Research
Biogen's third quarter 2017 earnings were better-than expected. Revenues also surpassed estimates during the quarter.
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
by Zacks Equity Research
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
by Zacks Equity Research
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
by Arpita Dutt
Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
Where to Find Value in Healthcare Stocks
by Tracey Ryniec
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.
Catabasis' DMD Candidate Slows Disease Progression, Stock Up
by Zacks Equity Research
Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience
by Zacks Equity Research
Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.
Celsion's Immunotherapy Candidate Impresses, Stock Surges
by Zacks Equity Research
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.